Mayzent Alternatives Compared
| Mayzent | Copaxone | Tecfidera |
|
|---|
| Mayzent (siponimod) | Copaxone (glatiramer) | Tecfidera (dimethyl fumarate) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Mayzent is an S1P receptor modulator that may be used to treat relapsing forms of multiple sclerosis in adults. It is only suitable for people with a certain CYP2C9 genetic type and genotype testing... View more |
Prescription only
Copaxone is a combination of four amino acids that may be given to treat relapsing forms of multiple sclerosis in adults. It has been shown to significantly reduce the number of relapses, but may be... View more |
Prescription only
Tecfidera is a disease-modifying drug that may be used to reduce disease progression and relapses in people with multiple sclerosis. Flushing and gastrointestinal effects are the most common initial... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Mayzent (siponimod) | More about Copaxone (glatiramer) | More about Tecfidera (dimethyl fumarate) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
||||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Mayzent has an average rating of 6.8 out of 10 from a total of 7 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 33% reported a negative effect. |
Copaxone has an average rating of 7.6 out of 10 from a total of 132 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 16% reported a negative effect. |
Tecfidera has an average rating of 6.3 out of 10 from a total of 98 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 28% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Mayzent side effects in more detail. |
See also: Copaxone side effects in more detail. |
See also: Tecfidera side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mayzent prices |
View all Copaxone prices and generic prices |
View all Tecfidera prices and generic prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other glatiramer brands include: Glatopa |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
30 hours |
1 hour |
1 hour |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 705 drugs are known to interact with Mayzent:
|
A total of 1 drugs are known to interact with Copaxone:
|
A total of 607 drugs are known to interact with Tecfidera:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
March 26, 2019 |
December 20, 1996 |
March 27, 2013 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.